AMGEN INC — Director's Dealing 2019

Nov 6, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2019-11-01

Reporting Person: Graham Jonathan P (EVP, Gen. Counsel & Secy.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-01	Common Stock	A	9176	—	Acquired	51853	Direct

Footnotes

F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 11/1/2021, 11/1/2022 and 11/1/2023, respectively.

F2: These shares include the following RSUs granted under the Company's equity plans: 1,001 RSUs which vest in one installment on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; 3,155 RSUs which vest in two installments of 1,041 on 4/27/2020 and 4/27/2021 and one installment of 1,073 on 4/27/2022; 3,158 RSUs which vest in two installments of 1,042 on 5/3/2021 and 5/3/2022 and one installment of 1,074 on 5/3/2023; and 9,176 RSUs which vest in two installments of 3,028 on 11/1/2021 and 11/1/2022 and one installment of 3,120 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3: These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.